Assuntos
Transtornos Plaquetários/diagnóstico , Plaquetas/patologia , Adolescente , Tempo de Sangramento , Transtornos Plaquetários/sangue , Transtornos Plaquetários/congênito , Transtornos Plaquetários/metabolismo , Plaquetas/metabolismo , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Testes de Função Plaquetária , Fator de von Willebrand/metabolismoRESUMO
Inherited platelet disorders are rare but they can have considerable clinical impacts, and studies of their causes have advanced understanding of platelet formation and function. Effective hemostasis requires adequate circulating numbers of functional platelets. Quantitative, qualitative and combined platelet disorders with a bleeding phenotype have been linked to defects in platelet cytoskeletal elements, cell surface receptors, signal transduction pathways, secretory granules and other aspects. Inherited platelet disorders have variable clinical presentations, and diagnosis and management is often challenging. Evaluation begins with detailed patient and family histories, including a bleeding score. The physical exam identifies potential syndromic features of inherited platelet disorders and rules out other causes. Laboratory investigations include a complete blood count, blood film, coagulation testing and Von Willebrand factor assessment. A suspected platelet function disorder is further assessed by platelet aggregation, flow cytometry, platelet dense granule release and/or content, and genetic testing. The management of platelet function disorders aims to minimize the risk of bleeding and achieve adequate hemostasis when needed. Although not universal, platelet transfusion remains a crucial component in the management of many inherited platelet disorders.
Assuntos
Transtornos Plaquetários/congênito , Antifibrinolíticos/uso terapêutico , Transtornos Plaquetários/diagnóstico , Transtornos Plaquetários/genética , Transtornos Plaquetários/terapia , Plaquetas/fisiologia , Terapia Combinada , Marcadores Genéticos , Testes Genéticos , Humanos , Fenótipo , Transfusão de PlaquetasRESUMO
Cytoskeleton is composed of more than 100 proteins and represents a dynamic network of the cellular cytoplasm. Cytoskeletal functions include spatial organization of cellular components, structural connection of the cell with external environment, and biomechanical force generation. Cytoskeleton takes part, at different levels, in all phases of platelet biogenesis: megakaryocyte (MK) differentiation, MK maturation, and platelet formation. In addition, it also plays a major role in each stage of platelet function. Inherited platelet disorders (IPDs) are a group of rare diseases featured by low platelet count and/or impaired platelet function. Over the past decade, the investigation of platelet biomechanics has become a major and highly relevant theme of research due to its implications at every stage of development of human life. The initial use of diverse biophysical techniques (e.g., micropipette aspiration, atomic force and scanning ion conductance microscopy, real-time deformability cytometry) started unraveling biomechanical features of platelets that are expected to provide new explanations for physiological and pathological mechanisms. Although the impact of cytoskeletal alterations has been largely elucidated in various IPDs' pathogenesis, the understanding of their impact on biomechanical properties of platelets represents an unmet need. Regarding IPDs, improving biomechanical studies seems promising for diagnostic and prognostic implications. Potentially, these characteristics of platelets may also be used for the prediction of bleeding risk. This review addresses the current available methods for biophysical investigations of platelets and the possible implementations in the field of IPDs.
Assuntos
Fenômenos Biomecânicos/fisiologia , Transtornos Plaquetários/congênito , Plaquetas/citologia , Citoesqueleto/metabolismo , Transtornos Plaquetários/diagnóstico , Transtornos Plaquetários/metabolismo , Plaquetas/fisiologia , Plaquetas/ultraestrutura , Matriz Extracelular/metabolismo , Humanos , Microscopia de Força Atômica/métodos , Imagem Óptica/métodosRESUMO
RasGRP2 is calcium and diacylglycerol-regulated guanine nucleotide exchange factor I that activates Rap1, which is an essential signaling-knot in "inside-out" αIIbß3 integrin activation in platelets. Inherited platelet function disorder caused by variants of RASGRP2 represents a new congenital bleeding disorder referred to as platelet-type bleeding disorder-18 (BDPLT18). We review here the structure of RasGRP2 and its functions in the pathophysiology of platelets and of the other cellular types that express it. We will also examine the different pathogenic variants reported so far as well as strategies for the diagnosis and management of patients with BDPLT18.
Assuntos
Transtornos Plaquetários/genética , Plaquetas/patologia , Fatores de Troca do Nucleotídeo Guanina/genética , Hemorragia/genética , Transtornos Plaquetários/congênito , Pré-Escolar , Feminino , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Hemorragia/congênito , Humanos , Lactente , Masculino , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo , Complexo Shelterina , Transdução de Sinais/genética , Proteínas de Ligação a Telômeros/metabolismoRESUMO
Inherited platelet disorders (IPDs) are a heterogeneous group of disorders caused by multiple genetic defects. Obtaining a molecular diagnosis for IPD patients using a phenotype- and laboratory-based approach is complex, expensive, time-consuming, and not always successful. High-throughput sequencing (HTS) methods offer a genotype-based approach to facilitate molecular diagnostics. Such approaches are expected to decrease time to diagnosis, increase the diagnostic rate, and they have provided novel insights into the genotype-phenotype correlation of IPDs. Some of these approaches have also focused on the discovery of novel genes and unexpected molecular pathways which modulate megakaryocyte and platelet biology were discovered. A growing number of genetic defects underlying IPDs have been identified and we will here provide an overview of the diverse molecular players. Screening of these genes will deliver a genetic diagnosis for about 40%-50% of the IPDs patients and we will compare different HTS applications that have been developed. A brief focus on gene variant interpretation and classification in a diagnostic setting will be given. Although it is true that successes in diagnostics and gene discovery have been reached, a large fraction of patients still remains without a conclusive diagnosis. In these patients, the sum of non-diagnostic variants in known genes or in potential novel genes might only be proven informative in future studies with larger patient cohorts and by data sharing among the diverse genome medicine initiatives. Finally, we still do not understand the role of the non-coding genome space for IPDs.
Assuntos
Transtornos Plaquetários/diagnóstico , Sequenciamento de Nucleotídeos em Larga Escala , Transtornos Plaquetários/congênito , Transtornos Plaquetários/genética , Estudos de Associação Genética , Variação Genética , Genótipo , HumanosRESUMO
Inherited platelet function disorders (IPFDs) represent a significant fraction of congenital hemorrhagic disorders, and may be associated with bleeding of considerable severity. IPFDs may be difficult to diagnose and a preliminary accurate clinical examination and an objective evaluation of the severity of the bleeding history are mandatory. The laboratory investigation of IPFDs should follow a rational algorithm based on a streamlined panel of laboratory tests with subsequent steps of increasing levels of complexity. First screening tests include platelet count, peripheral blood smear, light transmission aggregometry, measurement of platelet granule content and release, and the expression of glycoproteins by flow cytometry. Several of these tests have been largely employed, and a few validated, for the diagnosis of IPFDs and some recent developments are discussed. Point-of-care tests may provide the advantage of rapidity and the possibility to study platelet function in whole blood, but further studies are required to clarify their potential diagnostic application. Genotyping is recommended for some conditions (genotype/phenotype correlations, forms associated with a high risk of developing hematologic malignancies) but, especially when carried out by next-generation sequencing (NGS) techniques, needs to be critically evaluated taking into account clinical and laboratory phenotypes.
Assuntos
Transtornos Plaquetários/diagnóstico , Técnicas de Laboratório Clínico/métodos , Transtornos Plaquetários/congênito , Transtornos Plaquetários/genética , Estudos de Associação Genética , Sequenciamento de Nucleotídeos em Larga Escala , HumanosRESUMO
Mucocutaneous bleeding symptoms and/or persistent thrombocytopenia occur in individuals with congenital disorders of platelet function and number. Apart from bleeding, these disorders are often associated with additional hematologic and clinical manifestations, including auditory, immunologic, and oncologic disease. Autosomal recessive, dominant, and X-linked inheritance patterns have been demonstrated. Precise delineation of the molecular cause of the platelet disorder can aid the pediatrician in the detection and prevention of specific disorder-associated manifestations and guide appropriate treatment and anticipatory care for the patient and family.
Assuntos
Transtornos Herdados da Coagulação Sanguínea/diagnóstico , Transtornos Plaquetários/congênito , Transtornos Plaquetários/diagnóstico , Trombocitopenia/congênito , Trombocitopenia/diagnóstico , Transtornos Herdados da Coagulação Sanguínea/terapia , Transtornos Plaquetários/terapia , Humanos , Trombocitopenia/terapiaRESUMO
Excessive bleeding at surgery is a feared complication in patients with inherited platelet disorders. However, very few studies have evaluated the frequency of surgical bleeding in these hemorrhagic disorders. We performed a worldwide, multicentric, retrospective study to assess the bleeding complications of surgery, the preventive and therapeutic approaches adopted, and their efficacy in patients with inherited platelet disorders: the Surgery in Platelet disorders And Therapeutic Approach (SPATA) study. We rated the outcome of 829 surgical procedures carried out in 423 patients with well-defined forms of inherited platelet disorders: 238 inherited platelet function disorders and 185 inherited platelet number disorders. Frequency of surgical bleeding was high in patients with inherited platelet disorders (19.7%), with a significantly higher bleeding incidence in inherited platelet function disorders (24.8%) than in inherited platelet number disorders (13.4%). The frequency of bleeding varied according to the type of inherited platelet disorder, with biallelic Bernard Soulier syndrome having the highest occurrence (44.4%). Frequency of bleeding was predicted by a pre-operative World Health Organization bleeding score of 2 or higher. Some types of surgery were associated with a higher bleeding incidence, like cardiovascular and urological surgery. The use of pre-operative pro-hemostatic treatments was associated with a lower bleeding frequency in patients with inherited platelet function disorders but not in inherited platelet number disorders. Desmopressin, alone or with antifibrinolytic agents, was the preventive treatment associated with the lowest bleedings. Platelet transfusions were used more frequently in patients at higher bleeding risk. Surgical bleeding risk in inherited platelet disorders is substantial, especially in inherited platelet function disorders, and bleeding history, type of disorder, type of surgery and female sex are associated with higher bleeding frequency. Prophylactic pre-operative pro-hemostatic treatments appear to be required and are associated with a lower bleeding incidence.
Assuntos
Transtornos Plaquetários/congênito , Transtornos Plaquetários/complicações , Hemorragia/etiologia , Hemorragia/prevenção & controle , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Transtornos Plaquetários/diagnóstico , Criança , Pré-Escolar , Feminino , Hemorragia/epidemiologia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados da Assistência ao Paciente , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , Pré-Medicação/métodos , Medição de Risco , Fatores de Risco , Procedimentos Cirúrgicos Operatórios/métodos , Resultado do Tratamento , Adulto JovemRESUMO
: The diagnosis of inherited platelet disorders (IPDs) is challenging with variable diagnostic practices existing between institutions. To determine patterns and utility of diagnostic testing practices for IPDs within a single institution, a retrospective cohort study was performed. Records of 50 patients (50% women), median age 32 years (1 day to 81 years) were analyzed. In total, 28 (53%) had a positive International Society of Thrombosis and Hemostasis Bleeding Assessment Tool score. Test-ordering patterns were highly variable. All patients had platelet morphology analysis by light microscopy. In total, 42 (84%) underwent light transmission aggregometry, 43 (86%) platelet function analyzer, 37 (74%) platelet electron microscopy, 25 (50%) flow cytometry, and 15 (30%) genetic testing. Platelet function analyzer and light transmission aggregometry were always used as first-order tests, followed by platelet transmission electron microscopy and flow cytometry (81 and 84%, respectively). Genetic testing was obtained up front in five cases (33% of orders), mostly in patients with syndromic thrombocytopenia or in the setting of a known genetic disorder. Test-ordering practices did not adhere to published algorithms. Even within a single institution, great heterogeneity exists in the testing approach to IPDs. Although, a large proportion of cases were studied with platelet transmission electron microscopy and flow cytometry, standard platelet assays established the diagnosis in a great majority. Standardization of testing practices, first beginning at the institutional level is a much needed step forward.
Assuntos
Transtornos Plaquetários/congênito , Transtornos Plaquetários/diagnóstico , Testes de Função Plaquetária/normas , Padrões de Prática Médica/normas , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Transtornos Herdados da Coagulação Sanguínea/diagnóstico , Transtornos Plaquetários/genética , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Testes de Função Plaquetária/instrumentação , Estudos Retrospectivos , Adulto JovemRESUMO
Genetic diagnosis in families with inherited platelet disorders (IPD) is not performed widely because of the genetic heterogeneity of this group of disorders and because in most cases, it is not possible to select single candidate genes for analysis using clinical and laboratory phenotypes. Next-generation sequencing (NGS) technology has revolutionized the scale and cost-effectiveness of genetic testing, and has emerged as a valuable tool for IPD. This review examines the potential utility of NGS as a diagnostic tool to streamline detection of causal variants in known IPD genes and as a vehicle for new gene discovery.
Assuntos
Transtornos Plaquetários/diagnóstico , Genômica , Transtornos Plaquetários/congênito , Transtornos Plaquetários/genética , Testes Genéticos , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Fenótipo , Complexo Glicoproteico GPIb-IX de Plaquetas/genética , Análise de Sequência de DNA , Trombocitopenia/congênito , Trombocitopenia/diagnósticoRESUMO
The diagnosis of congenital and acquired bleeding disorders in infants requires an understanding of developmental haemostasis and the effect on laboratory testing. A systematic approach to bleeding in neonates will aid clinicians in the diagnosis and treatment, which may be caused by a wide variety of diseases. The clinical setting will help to direct the diagnostic pathway. This review will focus on the presentation and diagnosis of congenital and acquired bleeding disorders, including platelet disorders. Current research in this field is ongoing, including investigation into neonatal platelets and their different functionalities, platelet transfusion thresholds and how changes in coagulation factors may be linked to other homeostatic mechanisms.
Assuntos
Transtornos da Coagulação Sanguínea/congênito , Hemorragia/congênito , Transtornos da Coagulação Sanguínea/sangue , Transtornos da Coagulação Sanguínea/terapia , Fatores de Coagulação Sanguínea/uso terapêutico , Transtornos Plaquetários/sangue , Transtornos Plaquetários/congênito , Transtornos Plaquetários/terapia , Plaquetas/patologia , Plaquetas/fisiologia , Hemorragia/sangue , Hemorragia/terapia , Hemostasia/fisiologia , Humanos , Lactente , Recém-Nascido , Doenças do Recém-Nascido/sangue , Doenças do Recém-Nascido/etiologia , Doenças do Recém-Nascido/terapia , Trombocitopenia/sangue , Trombocitopenia/complicações , Trombocitopenia/congênito , Trombocitopenia/terapiaRESUMO
Inherited disorders of platelet function are a heterogeneous group. For optimal prevention and management of bleeding, classification and diagnosis of the underlying defect are highly recommended. An interdisciplinary guideline for a diagnostic approach has been published (AWMF # 086-003 S2K; Hämostaseologie 2014; 34: 201-212). Underlying platelet disorder, platelet count, age and clinical situation modify treatment. Exclusive transfusion of platelet concentrates may be inappropriate as potentially adverse effects can outweigh its benefit. A stepwise and individually adjusted approach for restitution and maintenance of haemostasis is recommended. Administration of antifibrinolytics is generally endorsed, but is of particular use in Quebec disease. Restricted to older children, desmopressin is favourable in storage pool disease and unclassified platelet disorders. Although licensed only for patients with Glanzmann thrombasthenia and alloantibodies, in clinical practice rFVIIa is widely used in inherited platelet disorders with severe bleeding tendency. This guideline aims at presenting the best available advice for the management of patients with inherited platelet function disorders.
Assuntos
Antiarrítmicos/uso terapêutico , Transtornos Plaquetários/congênito , Transtornos Plaquetários/terapia , Desamino Arginina Vasopressina/uso terapêutico , Fator VIIa/uso terapêutico , Hemorragia/terapia , Transfusão de Plaquetas/normas , Antiarrítmicos/normas , Transtornos Plaquetários/diagnóstico , Criança , Pré-Escolar , Feminino , Alemanha , Hematologia/normas , Hemorragia/congênito , Hemorragia/diagnóstico , Hemostáticos/uso terapêutico , Humanos , Lactente , Recém-Nascido , Masculino , Pediatria/normas , Guias de Prática Clínica como AssuntoRESUMO
Genetic defects of platelets constitute rare diseases that include bleeding syndromes of autosomal dominant, recessive or X-linked inheritance. They affect platelet production, resulting in a low circulating platelet count and changes in platelet morphology, platelet function, or a combination of both with altered megakaryopoiesis and a defective platelet response. As a result, blood platelets fail to fulfil their haemostatic function. Most studied of the platelet function disorders are deficiencies of glycoprotein mediators of adhesion and aggregation while defects of primary receptors for stimuli include the P2Y12 ADP receptor. Studies on inherited defects of (i) secretion from storage organelles (dense granules, α-granules), (ii) the platelet cytoskeleton and (iii) the generation of pro-coagulant activity have identified genes indirectly controlling the functional response. Signalling pathway defects leading to agonist-specific modifications of platelet aggregation are the current target of exome-sequencing strategies. We now review recent advances in the molecular characterization of platelet function defects.
Assuntos
Transtornos Herdados da Coagulação Sanguínea/genética , Transtornos Herdados da Coagulação Sanguínea/metabolismo , Transtornos Plaquetários/genética , Transtornos Plaquetários/metabolismo , Transtornos Plaquetários/congênito , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Humanos , Adesividade Plaquetária , Púrpura Trombocitopênica Trombótica/genética , Púrpura Trombocitopênica Trombótica/metabolismo , Receptores de Superfície Celular/metabolismo , Transdução de Sinais , Trombastenia/etiologia , Trombastenia/genética , Trombastenia/metabolismoRESUMO
Over the past 4 decades, a better understanding of the genetic origins of inherited platelet disorders has illuminated avenues of investigation in megakaryopoiesis and has identified targets of pharmacologic intervention. Many of these discoveries have been translated into clinical medicine. The success of inherited platelet disorder research is underpinned by broader advances in methodology through the biochemical and molecular revolution of the 20(th) and 21(st) centuries, respectively. Recently, modern genomics techniques have affected platelet and platelet disorders research, allowing for the discovery of several genes involved in platelet production and function and for a deeper understanding of the RNA and miRNA networks that govern platelet function. In this short review, we focus on recent developments in the genetic elucidation of several disorders of platelet number and in the molecular architecture that determines the "genetic makeup" of a platelet in health and disease.
Assuntos
Transtornos Plaquetários/congênito , Transtornos Plaquetários/genética , Transtornos Plaquetários/classificação , Transtornos Plaquetários/história , Predisposição Genética para Doença , Pesquisa em Genética , História do Século XX , HumanosRESUMO
Inherited thrombocytopenias vary in their presentation, associated features, and molecular etiologies. An accurate diagnosis is important to provide appropriate therapy as well as counseling for the individual and their family members. As the genetic basis of more disorders is understood, it will be possible to diagnose a greater fraction of patients as well as learn more about the process of megakaryopoiesis and platelet production.
Assuntos
Transtornos Plaquetários/congênito , Trombocitopenia/etiologia , Transtornos Plaquetários/diagnóstico , Transtornos Plaquetários/fisiopatologia , Transtornos Plaquetários/terapia , Síndrome Congênita de Insuficiência da Medula Óssea , Humanos , Megacariócitos/citologia , Megacariócitos/metabolismo , Megacariócitos/patologia , Rádio (Anatomia)/anormalidades , Rádio (Anatomia)/fisiopatologia , Sinostose/diagnóstico , Sinostose/genética , Sinostose/fisiopatologia , Sinostose/terapia , Trombocitopenia/congênito , Trombocitopenia/diagnóstico , Trombocitopenia/genética , Trombocitopenia/fisiopatologia , Trombocitopenia/terapia , Trombopoese , Ulna/anormalidades , Ulna/fisiopatologia , Deformidades Congênitas das Extremidades Superiores/diagnóstico , Deformidades Congênitas das Extremidades Superiores/genética , Deformidades Congênitas das Extremidades Superiores/fisiopatologia , Deformidades Congênitas das Extremidades Superiores/terapia , Doença de von Willebrand Tipo 2/diagnóstico , Doença de von Willebrand Tipo 2/genética , Doença de von Willebrand Tipo 2/fisiopatologia , Doença de von Willebrand Tipo 2/terapiaRESUMO
Hypogranular platelet disorders in human subjects are relatively rare. They include the gray platelet syndrome, αδ storage pool deficiency, the Hermansky-Pudlak syndrome, and the white platelet syndrome. Perhaps the rarest of them all is the Medich giant platelet disorder. No additional cases of this condition have been reported since description of the first case in 2004. This study describes two children with thrombocytopenia and giant, hypogranular platelets found shortly after birth. Electron microscopic study of their platelets revealed sheets of membrane wrapped into tubes resembling scrolls. The scroll-like structures were open at both ends and often filled with glycogen particles. The abnormal structures are identical to those found in the initial case. As a result, the disorder can now be referred to as the Medich giant platelet syndrome.
Assuntos
Síndrome de Bernard-Soulier/diagnóstico , Transtornos Plaquetários/congênito , Síndrome de Hermanski-Pudlak/diagnóstico , Deficiência do Pool Plaquetário/diagnóstico , Transtornos Plaquetários/diagnóstico , Plaquetas/ultraestrutura , Feminino , Humanos , Masculino , Trombocitopenia/diagnósticoRESUMO
Congenital abnormalities of platelet function disorder (PFD) are associated with the heightened risk for bleeding. Typically, patients with PFDs have mucocutaneous bleeding of variable severity and excessive hemorrhage after surgery or trauma. The diagnostic laboratory assessment appropriate for the evaluation of suspected inherited PFD should be based on a two-step diagnostic strategy: the first step, based on screening tests, helps raising a diagnostic hypothesis, which should then be tested in the second step, which is based on the use of specific tests. The first step should include: complete blood cell count, examination of the peripheral blood smear, and assessment of platelet aggregation. Although light transmission aggregometry (LTA) is the most widely used platelet function test, it is relatively insensitive to defects of platelet secretion; for this reason, laboratory tests that measure platelet aggregation and secretion simultaneously, such as lumi-aggregometry, should be preferred to traditional LTA. The second step includes specific tests (e.g., flow cytometry, Western blotting, DNA analysis). Platelet transfusions should be used only to treat severe bleeding episodes. Recombinant Factor VIIa can be used in patients with severe bleeding episodes who do not respond to platelet transfusion because of alloimmunization. Fibrinolytic inhibitors or the vasopressin analogue desmopressin (DDAVP) should be used in all other circumstances.
Assuntos
Transtornos Plaquetários/diagnóstico , Transtornos Plaquetários/terapia , Desamino Arginina Vasopressina/uso terapêutico , Fator VIIa/uso terapêutico , Hemorragia/diagnóstico , Hemorragia/terapia , Hemostáticos/uso terapêutico , Contagem de Células Sanguíneas , Transtornos Plaquetários/complicações , Transtornos Plaquetários/congênito , Plaquetas/efeitos dos fármacos , Plaquetas/fisiologia , Western Blotting , Citometria de Fluxo , Hemorragia/complicações , Hemorragia/congênito , Humanos , Agregação Plaquetária/efeitos dos fármacos , Testes de Função Plaquetária , Transfusão de Plaquetas , Proteínas Recombinantes/uso terapêutico , Análise de Sequência de DNARESUMO
Epistaxis, superficial and deep hematomas, hemarthrosis, gastrointestinal bleeding, hematuria represent the most frequent hemorrhagic events in congenital coagulation disorders. Occasionally, bleeding manifestations occur in unusual sites or are peculiar. A clotting defect may alter the clinical aspect of skin conditions or infections (hemorrhagic scabies or varicella). Hemobilia may occur as a complication of transjugular liver biopsy in hemophilia or Bernard-Soulier syndrome. Hemarthrosis of small joints of feet and hands occur in patients with hemophilia treated with protease inhibitors. Intramedullary hematomas of long bones have been described in α2-plasmin inhibitor or fibrinogen deficiencies. Spleen fracture with consequent hemoperitoneum has been reported in patients with fibrinogen deficiency. Rectus muscle sheath hematoma may occur in patients with factor VII (FVII)or FX deficiency. Acute or subacute intestinal obstruction may be caused by intramural wall hematomas in hemophilia and von Willebrand (vW)-disease. Physicians should always keep in mind that a congenital hemorrhagic disorder may cause bleeding in any tissue of the body and therefore alter the normal clinical features of a given disease.